Last reviewed · How we verify
Murine CART19
Murine CART19 is a Biologic drug developed by Stephan Grupp MD PhD. It is currently in Phase 2 development.
Murine CART19 is a protein-based intervention used to treat various conditions, including pediatric B cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and pancreatic cancer, among others. It is a form of CD19-directed chimeric antigen receptor T cells, derived from murine sources.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Murine CART19 |
|---|---|
| Sponsor | Stephan Grupp MD PhD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Orphan Indications for CD19 Redirected Autologous T Cells (PHASE2)
- Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas (PHASE2)
- Autologous CARTmeso/19 Against Pancreatic Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Murine CART19 CI brief — competitive landscape report
- Murine CART19 updates RSS · CI watch RSS
- Stephan Grupp MD PhD portfolio CI
Frequently asked questions about Murine CART19
What is Murine CART19?
Who makes Murine CART19?
What development phase is Murine CART19 in?
Related
- Manufacturer: Stephan Grupp MD PhD — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing